Sotera Health Co SHC

Healthcare SIC 8090 - Services-Misc Health & Allied Services, NEC NAICS Health Care and Social Assistance › Ambulatory Health Care Services › Outpatient Care Centers › Other Outpatient Care Centers › Kidney Dialysis Centers derived Nasdaq

We are a leading global provider of mission-critical end-to-end sterilization solutions, lab testing and advisory services for the healthcare industry. We are driven by our mission: Safeguarding Global Health®. We provide end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers in the United States and around the world. In 2025, our customers included over 40 of the top 50 medical device companies and nine of the top ten global pharmaceutical companies (based on revenue). Our services are an essential aspect of our customers' manufacturing processes and supply chains, helping to ensure sterilized medical products reach healthcare practitioners and patients. Most of our services are necessary for our customers to satisfy applicable government requirements.

Last close 18.10 2026-10-23
Market cap $5.17B 2026-06-30 share count
52-week range 13.09 - 19.85

Valuation FY2025 figures against the last close

P/S4.4x
P/E67.0x
P/FCF34.6x
EV/EBITDA—
Dividend yield—
Diluted EPS0.27

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • United States
  • Europe
  • Canada
  • Other
Revenue by geography, 4 categories over 3 years. The same figures are in the table below. FY2025 United States, FY2025: 629.5M (54.1%) 54% United States Europe, FY2025: 232.2M (20.0%) 20% Europe Canada, FY2025: 221.9M (19.1%) 19% Canada Other, FY2025: 79.9M (6.9%) 7% Other FY2024 United States, FY2024: 616.7M (56.0%) 56% Europe, FY2024: 196M (17.8%) 18% Canada, FY2024: 208.9M (19.0%) 19% Other, FY2024: 78.9M (7.2%) 7% FY2023 United States, FY2023: 591M (56.3%) 56% Europe, FY2023: 187.5M (17.9%) 18% Canada, FY2023: 192.1M (18.3%) 18% Other, FY2023: 78.7M (7.5%) 8%
Region FY2025FY2024FY2023
United States $629.5M $616.7M $591.0M
Europe $232.2M $196.0M $187.5M
Canada $221.9M $208.9M $192.1M
Other $79.9M $78.9M $78.7M

As the company reported it, from the “Segment and Geographic Information - Schedule of Revenues (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Revenue by segment

  • Sterigenics
  • Nelson Labs
  • Nordion
Revenue by segment, 3 categories over 3 years. The same figures are in the table below. FY2025 Sterigenics, FY2025: 755.8M (65.0%) 65% Sterigenics Nelson Labs, FY2025: 220.2M (18.9%) 19% Nelson Labs Nordion, FY2025: 187.6M (16.1%) 16% Nordion FY2024 Sterigenics, FY2024: 697.9M (63.4%) 63% Nelson Labs, FY2024: 229.2M (20.8%) 21% Nordion, FY2024: 173.4M (15.8%) 16% FY2023 Sterigenics, FY2023: 667.1M (63.6%) 64% Nelson Labs, FY2023: 221.7M (21.1%) 21% Nordion, FY2023: 160.5M (15.3%) 15%
Segment FY2025FY2024FY2023
Sterigenics $755.8M $697.9M $667.1M
Nelson Labs $220.2M $229.2M $221.7M
Nordion $187.6M $173.4M $160.5M

As the company reported it, from the “Segment and Geographic Information - Schedule of Segment Operating Results (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Segments are the filer's own reporting structure, which is a decision about how it runs itself rather than a standard taxonomy: two companies in the same industry routinely divide themselves along different lines, so these are worth reading down a single company rather than across two. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue $1.16B$1.10B$1.05B$1.00B$931.5M$818.2M$778.3M—
Cost of revenue $518.1M$498.1M$472.1M$446.7M$412.8M$374.6M$382.9M—
Gross profit $645.5M$602.3M$577.2M$557.0M$518.7M$443.6M$395.4M—
SG&A $252.8M$242.6M$236.7M$245.7M$198.2M$178.5M$147.5M—
Total operating expenses —$304.7M$300.5M$308.7M$261.9M$237.6M$211.8M—
Operating income —$297.6M$276.7M$248.3M$256.7M$206.0M$183.6M—
Pre-tax income $147.5M$113.9M$106.0M-$243.1M$175.7M-$38.9M-$916.0K—
Income tax $69.6M$69.5M$54.7M$9.5M$58.6M$1.4M$19.5M—
Net income $77.9M$44.4M$51.4M-$233.6M$116.2M-$38.6M-$20.9M—
EPS, basic 0.270.160.18-0.830.41-0.16-0.09—
EPS, diluted 0.270.160.18-0.830.41-0.16-0.09—
Shares, diluted (wtd. avg.) 286.4M284.9M283.2M280.1M279.4M237.7M232.4M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents $344.6M$277.2M$301.7M$396.3M$106.9M$102.5M$63.0M$96.8M
Receivables $139.3M$140.3M$147.7M$118.5M$108.2M$91.7M——
Inventory $54.4M$49.2M$48.3M$37.1M$54.3M$34.1M——
Total current assets $613.4M$526.0M$557.2M$645.0M$346.0M$315.0M——
Goodwill $1.10B$1.08B$1.11B$1.10B$1.12B$1.12B$1.04B—
Other intangibles $288.2M$317.7M$416.3M$491.3M$598.8M$643.4M——
Total assets $3.26B$3.07B$3.13B$3.12B$2.79B$2.76B——
Accounts payable $78.0M$55.1M$71.0M$74.1M$72.9M$52.4M——
Short-term debt $14.0M$14.8M$4.8M$197.1M$0$0——
Total current liabilities $249.6M$191.0M$230.7M$791.6M$161.2M$140.6M——
Long-term debt $2.13B$2.21B$2.22B$1.75B$1.74B$1.82B——
Total liabilities $2.66B$2.67B$2.69B$2.77B$2.20B$2.31B——
Retained earnings -$532.1M-$610.0M-$654.4M-$705.8M-$472.2M-$589.1M——
Total equity $606.0M$404.9M$443.7M$350.2M$586.1M$454.6M-$641.1M$45.5M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Operating cash flow $287.2M$224.2M-$147.7M$278.0M$281.5M$120.6M$149.0M—
Depreciation and amortisation $94.9M$84.3M$76.6M$64.3M$64.2M$63.3M$66.7M—
Stock-based compensation $30.9M$36.8M$32.2M$21.2M$13.9M$11.0M$6.9M—
Capital expenditure $138.0M$179.1M$215.0M$182.4M$102.2M$53.5M$57.3M—
Investing cash flow -$135.1M-$179.0M-$214.9M-$181.9M-$159.8M-$158.7M-$57.3M—
Financing cash flow -$100.5M-$50.6M$266.0M$197.8M-$117.3M$73.4M-$126.0M—
Dividends paid ————$0$0$691.2M—
Buybacks ———$0$0$34.0M$0—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-040937.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -500M 0 500M 1B 1.5B Revenue, FY2019: 778.3M Gross profit, FY2019: 395.4M Net income, FY2019: -20.9M Revenue, FY2020: 818.2M Gross profit, FY2020: 443.6M Net income, FY2020: -38.6M Revenue, FY2021: 931.5M Gross profit, FY2021: 518.7M Net income, FY2021: 116.2M Revenue, FY2022: 1B Gross profit, FY2022: 557M Net income, FY2022: -233.6M Revenue, FY2023: 1B Gross profit, FY2023: 577.2M Net income, FY2023: 51.4M Revenue, FY2024: 1.1B Gross profit, FY2024: 602.3M Net income, FY2024: 44.4M Revenue, FY2025: 1.2B Gross profit, FY2025: 645.5M Net income, FY2025: 77.9M FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — $778.3M $818.2M $931.5M $1.00B $1.05B $1.10B $1.16B
Gross profit — $395.4M $443.6M $518.7M $557.0M $577.2M $602.3M $645.5M
Net income — -$20.9M -$38.6M $116.2M -$233.6M $51.4M $44.4M $77.9M

Recent filings and events

  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced Item 2.02
  • Officer or director change Item 5.02
  • Officer or director change Item 5.02
  • Other event Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 8090

TickerCompanyMarket capP/ERevenue growth
DVA DAVITA INC. $11.72B 18.7x 6.5%
PGNY Progyny, Inc. $2.22B 44.6x 10.4%
AGL agilon health, inc. $1.51B — -2.1%
VMD VIEMED HEALTHCARE, INC. $373.3M 26.5x 20.5%
BRTX BioRestorative Therapies, Inc. $41.3M — -10.3%
CCEL CRYO CELL INTERNATIONAL INC $35.9M — -1.3%
MGRX MANGOCEUTICALS, INC. $5.0M — -26.0%
FMS Fresenius Medical Care AG — — —